Incidence of Benign and Malignant Neoplasms in Crohn's Disease Patients Aged ≤30 Years Versus 30‐64 Years Treated With Certolizumab Pegol: Results From a Pooled Safety Analysis of 15 Studies: 1831. (October 2015) - Choi, Jennifer; Ha, Christina; Kosutic, Gordana; Spearman, Marshall; Coarse, Jason; Hasan, Iram; Loftus, Edward V.